In addition, Zengarini et al. presented some treatment effects on BRAF V600K mutated melanoma patients [19], and there is also an ongoing phase 2 clinical trial on the application of dabrafenib and trametinib in tumors with the BRAF V600E or V600K mutation including non-small cell lung cancer (ClinicalTrials.gov Identifier: NCT04439292). Here, BRAF is linked to melanoma.